Related Experiment Video
Updated: May 24, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
BRCA and pancreatic cancer: selection of chemotherapy
Richard Kim1, Jenifer Byer, Muhammad Wasif Saif
1H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. richard.kim@moffitt.org
Abstract:
Germline mutations in BRCA genes are associated with increased risk of pancreatic cancer. There are pre clinical data which suggests that DNA cross linking agents should be used in pancreatic cancer patients with BRCA mutations. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of pancreatic cancer with BRCA mutation. Only one study (Abstracts #217) was presented and it is described here.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chronic Pancreatitis II: Collaborative Care
Assessment: